Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents

详细信息    查看全文

• 作者：Mariska C. Vlot^a ; ^b ; Daniel T. Klink^c ; ^d ; ^{d.klink@vumc.nl} ; Martin den Heijer^b ; ^c ; ^{m.denheijer@vumc.nl} ; Marinus A. Blankenstein^a ; ^{ma.blankenstein@vumc.nl} ; Joost Rotteveel^c ; ^d ; ^{j.rotteveel@vumc.nl} ; Annemieke C. Heijboer^a ; ^{a.heijboer@vumc.nl}
• 关键词：BMD ; bone mineral density ; BMAD ; bone mineral apparent density ; BTM ; bone turnover marker ; GnRHa ; gonadotropin-releasing hormone analogue ; CSHT ; cross-sex hormone therapy ; Female-to-male persons ; transmenMale-to-female persons  ; =  ; transwomen ; GA therapy ; gender affirming therapy ; FN ; femoral neck ; LS ; lumbar spine
• 刊名：Bone
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：95
• 期：Complete
• 页码：11-19
• 全文大小：1306 K
• 卷排序：95

文摘

The effect of puberty suppression and cross-sex hormone therapy on bone health in transgender adolescents is unknown. P1NP and 1CTP decreased during therapy with GnRHa and were even lower after 24 months of cross-sex hormone therapy. The lumbar spine BMAD and Z-scores increased after 24 months of cross-sex hormone therapy in transgender adolescents. Added value of BTM measurements seem to be limited, but DXA-scans remain important in follow-up of transgender adolescents.